

Kidney Cancer GCOM 10 (day 1) minutes

Kidney Cancer update – committee meeting 10 (day 1) minutes

Date: 20/03/2025

Location: Virtual

Minutes: Final

Committee members present:		
Axel Bex	Urological Surgeon	Present for items 2-4
Janet Brown	Medical Oncologist	Present for items 4-6
Amarnath Challapalli	Clinical Oncologist (General)	Present for items 1-8
Amy Clifford	Clinical Oncologist (SABR)	Present for items 1-8
John Connolly	Lay Member	Present for items 1-8
Stuart Evans	Oncology Pharmacist	Present for items 1-5
Geraldine Fox	Lay Member	Present for items 1-8
David Mole	Nephrologist (co-opted member)	Present for items 6-8
Ankit Rao	Medical Oncologist	Present for items 1-6
Ana Semedo	Vice Chair	Present for items 1-8
Sandeep Singh Randhawa	General Practitioner	Present for items 1-8
Grant Stewart	Topic Adviser	Present for items 2-8
Maxine Tran	Urological Surgeon	Present for items 1-8
Tze Min Wah	Interventional Radiologist	Present for items 1-8
Rose Woodward	Lay member	Present for items 4-8

In attendance NICE:		
Marie Harrisingh	Topic Lead	Present for items 1-8
Sarah Boyce	Senior Technical Analyst	Present for items 1-8
Danielle Conroy	Project Manager	Present for items 1-8
Lindsay Claxton	Health Economics Adviser	Present for items 1-8
Olivia Crane	Senior Technical Analyst	Present for items 1-8
Benjamin Gregory	Business Analyst, Resource Impact	Present for items 1-6
Tayyaba Mumtaz	Technical Analyst	Present for items 1-6
Jarin Noronha	National Medical Director's Clinical Fellow (Observing)	Present for items 1-5

Hannah Tebbs	Senior Health Economist	Present for items 1-8
Ellie Zachariades	Senior Guidance Content Designer	Present for items 1-8
Fernando Zanghelini	Technical Analyst	Present for items 1-8

Apologies:

Lisa Browning	Histopathologist, Committee member
Victoria Carter	Implementation Support Manager, NICE
David Cullen	Urology Cancer Nurse, Committee member
Fayiza Habeeb	Lead Nurse Practitioner, Committee member
Katherine Saxby	Medicines Adviser, Medicines Optimisation, NICE
Baljit Singh	Chair, Committee member
Sam Withey	Diagnostic Radiologist, Committee member
Yuanyuan Zhang	Senior Health Economist, NICE

1. Welcome, Introductions and DOIs

The Vice Chair, Ana Semedo (AS) welcomed the committee members and NICE attendees to day 1 of the 10th committee meeting for the NICE Kidney Cancer guideline.

AS informed attendees that apologies had been received as noted above. AS asked all committee members to verbally declare any new interests.

No new interests were declared but AS reminded the group of the following recorded interest which are relevant to the day's discussion:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Axel Bex	Consultant Urologist and Clinical Lead Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Specialist Centre for Kidney	De Bruijn, Roderick Emile, Mulders, Peter, Jewett, Michael A et al. (2019) Surgical Safety of Cytoreductive Nephrectomy Following Sunitinib: Results from the Multicentre, Randomised Controlled Trial of Immediate Versus Deferred Nephrectomy (SURTIME). European urology 76(4): 437-440 Bex, Axel, Mulders, Peter, Jewett, Michael et al. (2019) Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous	Direct-non-financial professional and personal	Declare and partial exclusion Study included in the evidence base for RQ6 part 1 however committee member's expertise is essential to this discussion. Participate in discussion but withdraw for drafting

Kidney Cancer GCOM 10 (day 1) minutes

	Cancer	Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial . JAMA oncology 5(2): 164-170 Declared 03/25.		recommendations.
Axel Bex	Consultant Urologist and Clinical Lead Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer	de Groot, Saskia, Redekop, William K, Sleijfer, Stefan et al. (2016) Survival in Patients With Primary Metastatic Renal Cell Carcinoma Treated With Sunitinib With or Without Previous Cytoreductive Nephrectomy: Results From a Population-based Registry . Urology 95: 121-7 Declared 03/25.	Direct-non-financial professional and personal	Declare and partial exclusion Study included in the evidence base for RQ6 part 1 however committee member's expertise is essential to this discussion. Participate in discussion but withdraw for drafting recommendations.
Axel Bex	Consultant Urologist and Clinical Lead Specialist Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer	Fransen van de Putte, Elisabeth E, van den Brink, Luna, Mansour, Mohamed A et al. (2023) Indications and Outcomes for Deferred Cytoreductive Nephrectomy Following Immune Checkpoint Inhibitor Combination Therapy: Can Systemic Therapy be Withdrawn in Patients with No Evidence of Disease? . European urology open science 55: 15-22 Declared 03/25.	Direct-non-financial professional and personal	Specific Declare and partial exclusion Study included in the evidence base for RQ6 part 2 however committee member's expertise is essential to this discussion. Participate in discussion but withdraw for drafting recommendations.

Axel Bex (AB) was an author on papers included in the evidence review being discussed. It was agreed that the member could stay for the discussion of the evidence of review questions 6b(i) and 6b(ii) but would need to step out whilst recommendations were being made.

Finally, the minutes from committee 9 (day 2) were checked and agreed to be an accurate record.

2. RQ 6b(i) (non-pharmacological interventions used before systemic anti-cancer therapy in adults with previously untreated advanced renal cell

carcinoma):

- **Presentation of clinical evidence**

The Vice Chair introduced Olivia Crane (OC), Senior Technical Analyst and Fernando Zanghelini (FZ) Technical Analyst.

OC presented a simplified clinical pathway to illustrate how the different parts of the review fit together before FZ presented the clinical evidence for non-pharmacological interventions used before systemic anti-cancer therapy in adults with previously untreated advanced renal cell carcinoma.

The committee had the opportunity to ask questions and discuss what was presented.

The Chair thanked OC and FZ for their presentation.

3. RQ 6b(ii) (non-pharmacological interventions used after systemic anti-cancer therapy for adults with advanced renal cell carcinoma):

- **Presentation of clinical evidence**

The Vice Chair introduced Tayyaba Mumtaz (TM), Technical Analyst who presented the clinical evidence for non-pharmacological interventions used after systemic anti-cancer therapy for adults with advanced renal cell carcinoma

The committee had the opportunity to ask questions and discuss what was presented.

The Chair thanked TM for her presentation.

4. RQ 6b(i) and 6b(ii):

- **Presentation of health economics**
- **Equality and health inequality considerations**
- **Committee discussion**

The Vice Chair introduced Hannah Tebbs (HT), Senior Health Economist who presented the health economics evidence for both pharma and non-pharmacological interventions used before and after systemic anti-cancer therapy.

The committee had the opportunity to ask questions and discuss the evidence for this review question in it's entirety, including if the data reflected what is usually seen in clinical practice and how much confidence they had in the studies included in the review.

TM and OC led the committee discussion on any equality and health inequality considerations in this area which needed to be documented.

5. Drafting recommendations for RQ6b

AB left the meeting at this point due to a conflict of interest.

Taking input from the committee to draft the initial wording, the NICE team were able to draft recommendations for the use of both pharma and non-pharmacological interventions used before and after systemic anti-cancer therapy that would be taken away for further edits.

6. Drafting recommendations for RQ6b (continued)

The Committee continued to draft recommendations including recommendations for research in this area.

AS thanked the committee for their input.

7. Revisiting recommendations:

- **RQ5a (active surveillance)**

The Chair introduced Marie Harrisingh (MH), Topic Lead who presented the previously drafted recommendations for active surveillance for further committee input. The committee had the opportunity to provide their expert input on several queries NICE team had including revision to wording.

AS thanked MH for her contribution.

8. Next steps and AOB

AS summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, AS brought the meeting to a close.

Date of next meeting: 26/03/2025

Location of next meeting: Virtual